Lipodystrophy syndrome in HIV-infected children on HAART

Southern African Journal of HIV Medicine

Volumn , Issue 36, 2009, Pages 76-80

  Innes, Steve ^a   Levin, Leon ^b   Cotton, Mark ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b RIGHT TO CARE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; FILLER; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; LAMIVUDINE; METFORMIN; STAVUDINE; TENOFOVIR; URIDINE; ZIDOVUDINE;

ARTICLE; BREAST DISEASE; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESTYLE MODIFICATION; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; LIPOMASTIA; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; RISK FACTOR; SKINFOLD THICKNESS; UNSPECIFIED SIDE EFFECT;

EID: 75749113709     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajhivmed.v10i4.264     Document Type: Article

References (50)

1. Meyers T, Eley B, Loening W. Khomanani Guidelines for the Management of HIV-infected Children. Johannesburg: National Department of Health, Jacana Media, 2005.
2. Hogan B (National Minister of Health - South Africa). Southern African AIDS Conference, Durban, April 2009. Plenary address, 3 April. http://www.saaids.com/images/stories/4th-SA-AIDS-Conference-presentations/ minister%20of%20health.pdf (accessed 16 November 2009).
3. McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004; 18: 1753-1768.
4. Aldrovandi GM, Lindsey JC, Jacobson DL, et al, for the Pediatric AIDS Clinical Trials Group P1045 team. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009; 23: 661-672.
5. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163(9): 860-869.
6. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther 2007; 12(8): 1247-1254.
7. Ene L, Goetghebuer T, Hainaut M, et al. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr 2007; 166(1): 13-21.
8. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001 ; 32: 130-139.
9. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998; 338: 1650-1656.
10. Girardet JP. Dyslipidemia in childhood and cardiovascular risk. Arch Pediatr 2009; 16: 692-693.
11. Walker UA Bickel M, Lütke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29(2): 117-121.
12. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000; 275: 41325-41332.
13. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811-820.
14. Hurst M, Noble S. Stavudine: an update of its use in the treatment of HIV infection. Drugs 1999; 58(5): 919-949.
15. Dragovic G, Jevtovic DJ. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antivir Chem Chemother 2003; 14(5): 281-284.
16. Montaner JS, Cote HC, Harris M, et al. Mitochondrial toxicity in the era of HAART: Evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34: Suppl 1, S85-S90.
17. Petit C Mathez D, Barthelemy C, Leste-Lasserre T, Naviaux RK, Sonigo P, leibowitch J. Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion. J Acquir Immune Defic Syndr 2003; 33: 461-469.
18. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001 ; 86: 504-510.
19. Parker RA, Flint OP, Mulvey R, et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 2005; 67: 1909-1919.
20. Jones SP, Qazi N, Morelese J, et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 2005; 40: 565-572.
21. Mallewa JE, Wilkins E, Vilar J, et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother 2008; 62(4): 648-660.
22. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. Acquir Immune Defic Syndr 2006; 20: 2043-2050.
23. Arranz Caso J, de Miguel Prieto J, Casas E, Sanz J. Gynecomastia without LD syndrome in HIV-infected men treated with efavirenz. AIDS 2001; 15: 1447-1448.
24. Merciéa P, Viallarda JP, Thiébaut R, et al. Efavirenz-associated breast hypertrophy in HIV-infected patients. AIDS 2001; 15(1): 126-129.
25. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. Acquir Immune Defic Syndr 1999; 13: F63-70.
26. McComsey GA, Walker UA. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion 2004; 4: 111-118.
27. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Antiretroviral therapy-associated toxicities in the resource-poor world: The challenge of a limited formulary. J Infect Dis 2007; 196: S449-S456.
28. ter Hofstede HJM, Koopmans PP, Burger DM. Stavudine plasma concentrations and lipoatrophy. J Antimicrob Chemother 2008; 61(4): 933-938.
29. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment Expert Opin Pharmocother 2007; 8(5): 679-688.
30. Addendum to 2006 WHO guidelines on antiretroviral therapy for HIV infection in adults and adolescents, www.who.int/hiv/en/ (accessed 26 August 2008).
31. Sánchez-Conde M, de Mendoza C, Jiménez-Nacher I, et al. Reductions in stavudine dose ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005; 6(4): 197-202.
32. McComsey GA, LoRe V III, O'Riordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density and markers of mitochondrial toxicity in HIV-infected subjects - a randomized, controlled study. Clin Infect Dis 2008; 46(8): 1290-129a
33. Amaya RA, Kozinetz CA, Mcmeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21:405-410.
34. Kaul S, Kline MW, Church JA, Dunkle LM. Determination of dosing guidelines for stavudine (2′,3′-didehydro-3′-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 2001 ; 45(3): 758-763.
35. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995; 96(2): 247-252.
36. Dudley MN, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166: 480-485.
37. Hendrickson SL, Kingsley LA, Ruiz-Pesini E, et al. Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51(2): 111-116.
38. Carr A, Emery S, Law M, Puis R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726-735.
39. Hartman K, Verweel G, de Groot R, Hartwig NG. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25(5): 427-431.
40. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18: 1443-1451.
41. Podzamczer D, Ferrer E, Martinez E, et al, for the ABCDE Study Team. How much fat loss is needed for lipoatrophy to become clinically evident? AIDS Res Hum Retroviruses 2009; 25(6): 563-567.
42. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17: 851-859.
43. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284: 472-777.
44. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: A systematic review. Diabetes Care 2009; 32(9): 1743-1745.
45. Riordan A, Judd A, Boyd K, Cliff D, et al, on behalf of the CHIPS Study. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J 2009; 28: 204-209.
46. McComsey GA, Ward DJ, Hessenthaler SM, et al, for the TARHEEL study team (Trial to Assess the Regression of Hyperlactatemia and to Evaluate the regression of Established Lipodystrophy in HIV-1-positive subjects). Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-270.
47. Fisher M, Moyle G, Shahmanesh M, et al. for the SWEET study group. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2009; 51: 562-568.
48. Carey DL, Baker D, Rogers GD, et al., for the Facial LipoAtrophy Study in HIV (FLASH). A randomized, multicenter, open-label study of pory-L-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr 2007; 46: 581-589.
49. McComsey GA, O'Riordan M, Setzer B, et al. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr 2008; 62: 1031-1037.
50. Falutz J, Alias S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007; 357: 2359-2370.